[Federal Register Volume 74, Number 177 (Tuesday, September 15, 2009)]
[Notices]
[Page 47253]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-22118]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case.
    Jennifer N. Arriaga, Universidad Central Del Caribe: Based on the 
findings of an investigation report by the Universidad Central Del 
Caribe (UCC) and additional analysis and information obtained by the 
Office of Research Integrity (ORI) during its oversight review, ORI 
found that Jennifer N. Arriaga, former Research Assistant in a clinical 
trial project entitled Brief Strategic Family Therapy for Adolescent 
Drug Abusers (BSFT) at UCC, engaged in research misconduct in research 
funded by National Institute on Drug Abuse (NIDA), National Institutes 
of Health (NIH), cooperative agreement U10 DA13720.
    Specifically, ORI found that Ms. Arriaga knowingly and 
intentionally engaged in research misconduct by fabricating 17 
interviews and falsifying 10 subject incentive receipts in the BSFT. 
The interview record consisted of Timeline Follow Back information, 
confidentiality self-report forms, and urine drug test results.
    The following administrative actions have been implemented for a 
period of two (2) years, beginning on August 18, 2009:
    (1) Ms. Arriaga is debarred from eligibility for any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility or involvement in nonprocurement programs of the United 
States pursuant to HHS' Implementation (2 CFR part 276 et seq.) of OMB 
Guidelines to Agencies on Governmentwide Debarment and Suspension (2 
CFR part 180); and
    (2) Ms. Arriaga is prohibited from serving in any advisory capacity 
to the U.S. Public Health Service (PHS), including but not limited to 
service on any PHS advisory committee, board, and/or peer review 
committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852. (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. E9-22118 Filed 9-14-09; 8:45 am]
BILLING CODE 4150-31-P